Rapid hemostatic material and application thereof

Abstract

The invention discloses a rapid hemostatic material, and belongs to the technical field of hemostatic materials, and the hemostatic material has low toxicity, low heat release and structural stability. The hemostatic material comprises a metal organic framework material or a mixture of a plurality of metal organic framework materials; the metal organic framework material is obtained by coordination of metal aluminum ions and organic ligands, and the organic ligands are selected from one or more of phthalic acid, isophthalic acid, trimesic acid, fumaric acid and other substances and derivatives thereof. Compared with a zeolite hemostatic material, the hemostatic material disclosed by the invention has the advantages of high hemostatic speed, mild hemostatic reaction and less heat release; compared with other metal organic framework hemostatic materials, the hemostatic material disclosed by the invention has the characteristics of high structural stability and high biocompatibility.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of hemostatic materials, and particularly relates to a rapid hemostatic material which is stable in structure and safe to use. BACKGROUND

[0002] Excessive blood loss can cause coagulopathy, hypothermia and acidosis (i.e. "the triad of death") in the human body, which is the main cause of trauma death. Globally, nearly 2 million people die each year due to failure to stop bleeding in time in traffic accidents, surgeries, wars, traffic accidents and natural disasters, highlighting the urgent need for rapid hemostatic materials and technologies.

[0003] At present, commonly used hemostatic materials include organic polymer materials (such as chitosan, modified starch, etc.), biological research materials (such as thrombin, animal-derived fibrin, etc.) and inorganic mineral materials (such as montmorillonite, kaolin, zeolite, etc.). Compared with the first two types of hemostatic materials, inorganic mineral hemostatic materials are favored due to their low cost, stable properties, storage resistance, long shelf life and many other advantages. However, inorganic mineral hemostatic materials also face many problems, for example, kaolin-based hemostatic materials rely on the host's coagulation function, and the hemostasis is not fast enough. The zeolite-based hemostatic material releases a large amount of heat during the hemostatic process, causing burns to the surrounding tissue. Although the pre-hydration method reduces the heat release of the zeolite material during the hemostatic process, it is accompanied by the negative effect of decreased hemostatic effect. Therefore, zeolite-based hemostatic materials cannot simultaneously achieve rapid hemostasis and avoid secondary burns. In order to solve the serious heat release problem of zeolite-based hemostatic materials, Chinese patent (CN107261199A) obtains a composite hemostatic material by compounding macromolecular protein human collagen and zeolite, which shortens the hemostatic time and also improves the problem of zeolite hemostatic heat release; Chinese patent (CN109999216A) discloses a trauma hemostatic sponge, which specifically comprises zeolite and graphene, and uses the high heat conduction capacity of graphene to quickly disperse the heat generated by the zeolite to avoid thermal damage. The above-mentioned solutions can improve the problem of zeolite material hemostatic heat release to some extent, but they will introduce other problems, such as high cost, poor stability of biological pharmaceuticals and weak resistance to release.

[0004] In recent years, metal-organic framework (MOF) materials have been widely used in catalysis, gas storage and separation, and medical fields due to their large specific surface area, high porosity, and easy-to-control structure and composition. Among them, MOFs materials are widely used as antibacterial agents or antibacterial agent carriers in the medical field due to their own characteristics. For example, Chinese patent (CN120324671A) uses Cu / ZIF-8 to load curcumin to obtain a pH-responsive antibacterial agent. In the environment of the wound where bacteria are generated (weakly acidic), the Cu / ZIF-8 structure is destroyed, and Cu 2+ and Zn 2+Furthermore, Chinese patent (CN117258028A) discloses a bimetallic MOF hydrogel dressing that promotes wound healing, in which the bimetallic MOF acts as an antibacterial agent, achieving antibacterial effects through the sustained release of metal ions. In addition, some MOF materials can act as nanoenzymes, exerting their own antibacterial effects. For example, Chinese patent (CN 117924537A) discloses a Cu-MOF / GOX functionalized chitosan-arginine thermosensitive hydrogel, in which the glucose oxidase-modified Cu-MOF exhibits POD activity, providing strong bactericidal efficacy at infected wound sites; Chinese patent (CN119548665A) discloses a composite hydrogel that promotes wound healing containing Ag / Cu-MOF, possessing superoxide dismutase-like and glutathione peroxidase-like activities, capable of scavenging excess reactive oxygen species and alleviating inflammatory responses. Besides serving as antibacterial agents, MOFs (Metal-Oxide-Fibers) can also be used as hemostatic agents in the medical field. For example, Chinese patent (CN119463202A) enhances thrombin activity by regulating different exposed crystal facets of ZIF-8. This technology essentially utilizes specific crystal facets to adsorb thrombin in blood and activate its activity. Furthermore, Chinese patent (CN117026631A) discloses an electrospun nanofiber membrane in situ loaded with ZIF-8, overcoming the weakness of hemostatic components in most hemostatic bandages, which are prone to detachment and poor adhesion to the substrate. Both patents use ZIF-8 as the active hemostatic agent, achieving hemostasis by exposing specific crystal facets {100} and {110} of ZIF-8 during the preparation process to adsorb and activate thrombin activity. This technology faces the following drawbacks: 1) ZIF-8 is structurally unstable and easily decomposes to produce 2-methylimidazole, and imidazole organic ligands are biotoxic; 2) Regulation requires specific synthetic methods, and the preparation technology is demanding; 3) This hemostatic mechanism is not universal and cannot be extended to other MOF types. Besides ZIF-8 as a hemostatic agent, Chinese patent (CN115869460A) discloses a nanogel self-adhesive powder for wound antibacterial and hemostatic purposes, comprising a Mg-MOF (magnesium-gallic acid; Mg-GA) loaded with an antibacterial agent and a hydrogel. The hydrogel plays a major hemostatic role, while the Mg-MOF, as a carrier of the antibacterial agent, decomposes after interacting with water in the blood, yielding Mg... 2+ Gallic acid and gallic acid have some hemostatic effect, but the hemostatic effect is weak and they do not have the ability to stop bleeding quickly when used alone.

[0005] In summary, the challenges faced by zeolite hemostatic materials, such as exothermic hemostasis, inflammation caused by zeolite residues, abscess formation, and even thrombosis due to blockage of peripheral arteries, remain unresolved. While ZIF-8, often used as an antibacterial agent, possesses some hemostatic ability, its structural stability is insufficient, and the imidazole ligands produced during decomposition exhibit some biotoxicity. Furthermore, specific regulatory methods are required to expose crystal facets that enhance coagulation. Moreover, the hemostatic mechanism of ZIF-8 is specific, lacking reference and universality for developing other MOF materials with hemostatic capabilities. Similarly, Mg-MOFs are prone to decomposition during hemostasis, limiting their hemostatic ability and preventing rapid hemostasis. Summary of the Invention

[0006] To address the aforementioned issues, such as the trade-off between rapid hemostasis and prevention of burns in zeolite-based hemostatic materials, the hemostatic specificity of ZIF-8 and the biotoxicity of its decomposition products, and the insufficient hemostatic ability of Mg-MOF, this invention provides a metal-organic framework (MOF) hemostatic material. This MOF hemostatic material exhibits rapid hemostasis with minimal heat release during the hemostasis process, preventing secondary damage such as tissue burns, inflammation, and thrombosis. Furthermore, the hemostatic material possesses a stable structure, avoiding hemostatic failure due to structural decomposition and the generation of biotoxic products, thus demonstrating excellent safety in use.

[0007] To achieve the above objectives, the present invention adopts the following technical solution.

[0008] This invention provides a low-toxicity and structurally stable rapid hemostatic material, wherein the hemostatic material is a metal-organic framework material formed by metal ions and organic ligands; wherein the metal ions are aluminum ions.

[0009] Further, the organic ligand includes one or more of terephthalic acid, isophthalic acid, trimesic acid, fumaric acid, 2,5-furandicarboxylic acid, 3,5-pyrazoledicarboxylic acid, amino acids, citric acid, malic acid, succinic acid, polypeptides, sugars, adipic acid, sebacic acid, and derivatives of the above substances. Preferably, the organic ligand includes one or more of terephthalic acid, isophthalic acid, trimesic acid, fumaric acid, and derivatives of the above substances.

[0010] Furthermore, the structural stability refers to the fact that the hemostatic material does not decompose within a pH range of 2-11. This structural stability ensures that the hemostatic material does not decompose when applied to different wound tissues with varying pH levels, thus guaranteeing its hemostatic efficacy. The structural stability also ensures that the hemostatic material will not produce biotoxic decomposition products, such as the decomposition product 2-methylimidazole of ZIF-8.

[0011] Furthermore, the BET specific surface area of ​​the hemostatic material is not less than 600 m².2 / g.

[0012] Furthermore, the hemostatic material has a particle size of not less than 200 nm and will not produce nanotoxicity.

[0013] The present invention provides the above-mentioned hemostatic material, which can be used as a hemostatic active ingredient in various hemostatic pharmaceuticals, such as hemostatic dressings, hemostatic gauze, hemostatic bandages, hemostatic sponges, hemostatic cotton balls, hemostatic gels, and hemostatic adhesive bandages.

[0014] The beneficial effects of this invention are as follows: 1) Compared with existing zeolite hemostatic materials, the hemostatic material of this invention has the characteristics of good hemostatic effect, mild hemostatic reaction and small temperature rise at the wound site, which can ensure rapid hemostasis while avoiding burns caused by temperature rise; 2) Compared with ZIF-8 hemostatic agent, the hemostatic material disclosed in this invention has strong structural stability and good biocompatibility, and will not produce biotoxic decomposition products (such as 2-methylimidazole, the decomposition product of ZIF-8); and does not require special preparation methods to expose certain specific crystal faces or regulate morphology, thereby adsorbing and activating coagulation factors; 3) Compared with Mg-MOF (Mg-GA) hemostatic agent, the hemostatic material disclosed in this invention has a stable structure, will not have a reduced hemostatic effect due to material decomposition, and has rapid hemostatic ability. Attached Figure Description

[0015] Figure 1 The XRD patterns of the hemostatic material in Example 1 of this invention after soaking in solutions with different pH values ​​for 7 days are compared.

[0016] Figure 2 This is a graph showing the temperature change inside the test tube after the zeolite material absorbs water in Comparative Example 3 of this invention.

[0017] Figure 3 This is a graph showing the temperature change inside the test tube after the hemostatic material absorbs water in Example 1 of the present invention.

[0018] Figure 4 This is a cytotoxicity test diagram of the hemostatic material in Embodiment 1 of the present invention.

[0019] Figure 5 This is a cytotoxicity test diagram of the hemostatic material in Example 4 of the present invention.

[0020] Figure 6 This is a cell viability diagram of the hemostatic material in Embodiment 1 of the present invention. Detailed Implementation

[0021] The following embodiments further illustrate the content of the present invention, but should not be construed as limiting the present invention. All other content obtained by making several equivalent improvements and simple modifications to the present invention without departing from the spirit and essence of the present invention falls within the scope of the present invention. Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art. Example 1

[0022] The hemostatic material in this embodiment is a metal-organic framework (MOF) material with aluminum ions as metal nodes and fumaric acid as ligand: Al-Fum (MIL-53(Al)-FA), CAS No.: 1370461-06-5, molecular formula: C4H2O5Al, molecular weight: 157.037 g / mol, and specific surface area as shown in Table 1; the MIL-53(Al)-FA used in this embodiment has a surface area of ​​not less than 200 nm.

[0023] This embodiment explored the hemostatic effect of the hemostatic material MIL-53(Al)-FA through a rat tail-cutting hemostasis experiment, confirming its excellent hemostatic efficacy. Details are as follows: The experiment was conducted in a barrier system laboratory that met the following conditions: air cleanliness ≤ 10,000, air exchange rate 10–20 times / hour, temperature 20–26 ℃, daily temperature difference ≤ 3 ℃, and relative humidity 40–70%; and provided a 12-hour light and 12-hour dark cycle. Rats were acclimatized in this barrier system laboratory for one week, with ample food and water provided.

[0024] Three rats were anesthetized by isoflurane inhalation. The tail was marked 4 cm from the tip of the tail, and the tail was cut off at the marked point after disinfection with iodine. The rats were then allowed to bleed naturally into the bottle. 3 g of hemostatic material MIL-53(Al)-FA was weighed into the bottle beforehand. Bleeding time was 2 minutes for each rat. The bottle was weighed again after 2 minutes, and the amount of blood loss for each rat was calculated.

[0025] Example 2

[0026] The hemostatic material in this embodiment is a metal-organic framework (MOF) material with aluminum ions as metal nodes and 2,5-furandicarboxylic acid (2,5-FDCA) as ligand: MIL-160(Al), CAS No.: 2050043-43-9, molecular formula: C6H3O6Al, molecular weight: 198.07 g / mol, and specific surface area as shown in Table 1; the MIL-160(Al) used in this embodiment has a surface area of ​​not less than 200 nm.

[0027] Similar to Example 1, this embodiment explored the hemostatic effect of the hemostatic material MIL-160(Al) through a rat tail-cutting hemostasis experiment, and confirmed that it also has a good hemostatic effect. Example 3

[0028] The hemostatic material in this embodiment is a metal-organic framework (MOF) material, namely CAU-10, with aluminum ions as the metal nodes and isophthalic acid (CAS: 121-91-5) as the ligand: CAU-10, CAS number: 1416330-84-1. Its chemical name is aluminum carboxyhydroxyaluminate 1,3-phthalic acid, and its aliases include aluminum hydroxide aluminate MOF, CAU-10-H, etc. Its molecular formula is C8H4AlO5 or Al(OH)(C8H4O4). x (x=0.9-1.0, molecular weight: approximately 207.104 g / mol, specific surface area as shown in Table 1; the particle size of MIL-160(Al) used in this embodiment is not less than 200 nm.)

[0029] Similar to Example 1, this embodiment explored the hemostatic effect of the hemostatic material CAU-10 through a rat tail-cutting hemostasis experiment, and confirmed that it also has a good hemostatic effect.

[0030] Example 4

[0031] The hemostatic material in this embodiment is a metal-organic framework (MOF) material with aluminum ions as the metal nodes and isophthalic acid as the ligand: MIL-100(Al), CAS No.: 1200358-58-2, molecular formula: C 18 H 10 Al3O 17 Molecular weight: approximately 579.21 g / mol, specific surface area as shown in Table 1; the particle size of MIL-160(Al) used in this embodiment is not less than 200 nm.

[0032] Similar to Example 1, this embodiment explored the hemostatic effect of the hemostatic material MIL-100(Al) through a rat tail-cutting hemostasis experiment, and confirmed that it also has a good hemostatic effect.

[0033] Comparative Example 1 The hemostatic material in Example 1 was replaced with ZIF-8, and the hemostatic experimental procedure remained unchanged from Example 1. The ZIF-8 in this comparative example was prepared according to the preparation process in CN119463202A. During the preparation of this hemostatic material, different crystal facets {100} and {110} exposed by ZIF-8 were controlled, utilizing these specific crystal facets to adsorb thrombin from the blood.

[0034] Comparative Example 2 The hemostatic material in Example 1 was replaced with Mg-GA (magnesium-gallic acid MOF), while the rest remained unchanged.

[0035] Comparative Example 3 The hemostatic material in Example 1 was replaced with zeolite material, while the rest remained unchanged.

[0036] Comparative Example 4 The hemostatic material in Example 1 was replaced with Yunnan Baiyao hemostatic powder, while the rest remained unchanged.

[0037] Comparative Example 5 In the blank experiment, no hemostatic materials were used in the examples, but everything else remained the same.

[0038] The aluminum-based metal-organic framework materials used in each embodiment must meet certain conditions in terms of specific surface area, particle size, and acid-base stability to achieve the hemostatic effect as performed in each embodiment. For example, the specific surface area of ​​the material is crucial, as it is related to its hemostatic mechanism. The hemostatic material disclosed in this invention relies on its strong water absorption to rapidly absorb water from the blood, concentrate hemostatic factors (such as platelets, thrombin, fibrinogen, etc.), accelerate the coagulation process, reduce bleeding, and achieve rapid hemostasis. Furthermore, the intrinsic specific surface area of ​​the material reflects the number of hydrophilic sites; the larger the specific surface area, the more hydrophilic sites it has, the faster the water adsorption rate, and the better the hemostatic effect. Furthermore, the ability to adsorb water from blood is also related to the composition of the material. For example, ZIF-8 in Comparative Example 1 is hydrophobic, and its hemostatic mechanism differs from that of the hemostatic materials in the embodiments of this invention. It is also related to the structural stability of the material. If the material is easily decomposed, it loses the prerequisite for water adsorption, such as Mg-GA in Comparative Example 1. The hemostatic materials selected in the embodiments of this invention all meet the requirement that their structure does not decompose within the pH range of 2-11. This structural stability of the hemostatic material ensures that it does not decompose when applied to microenvironments with different pH values ​​in different wound tissues, thus guaranteeing the effectiveness of its hemostatic efficacy. Structural stability also ensures that the hemostatic material does not produce biotoxic decomposition products. In addition, the hemostatic performance of the hemostatic materials selected in the embodiments is also related to the pore structure of the material. For example, materials with steric hindrance will have weakened water adsorption kinetics. In summary, the selection of hemostatic materials in each embodiment is a comprehensive consideration of numerous factors, such as composition, structure, particle size, biocompatibility, and stability. The hemostatic effect is also achieved through the synergistic effect of these numerous factors, rather than being determined by a single specific factor. For example, ZIF-8 in Comparative Example 1 also has a specific surface area greater than 600 μm. 2 / g (BET), but its hydrophobicity affects its ability to rapidly adsorb water in the blood and concentrate hemostatic factors. Therefore, ZIF-8 requires special modifiers and processing steps to adsorb and activate thrombin activity in the blood through specific crystal facets {100} and {110} in order to achieve a good hemostatic effect; in addition, ZIF-8 has insufficient structural stability and is prone to decomposition products, which have certain biological toxicity.

[0039] The material characterization of the hemostatic materials in each embodiment and comparative example is as follows: Specific surface area: As mentioned above, the specific surface area of ​​the material is crucial. The specific surface area test results of the hemostatic materials in the examples and comparative examples are listed in Table 1. It can be seen that the specific surface area of ​​the hemostatic material in the examples is much larger than that of the hemostatic material in the comparative examples, reflecting that the water absorption capacity of the hemostatic material in the examples is significantly better than that of the hemostatic material in comparative example 2.

[0040] Table 1. Specific surface area (BET) of hemostatic materials in the examples and comparative examples. Material name BET / m 2 / g]]> Example 1 MIL-53-FA 1200 Example 2 MIL-160 1100 Example 3 CAU-10 620 Example 4 MIL-100 2000 Comparative Example 2 Mg-GA 115 Structural stability: To demonstrate the excellent structural stability of the published hemostatic materials, ensuring they do not decompose in different wound tissue microenvironments with pH values ​​ranging from 2 to 12, the hemostatic materials from each example were immersed in solutions of different pH values ​​for 7 days, and the XRD patterns of the materials were compared. For example... Figure 1 The image shows the XRD patterns of the hemostatic material Al-Fum (MIL-53(Al)-FA) from Example 1 after immersion in solutions with different pH values ​​within the pH range of 2-12 for 7 days. Figure 1 As can be seen, the XRD pattern of Al-Fum (MIL-53(Al)-FA) after immersion for 7 days is consistent with the initial structure, indicating that the material structure has no significant changes before and after immersion, proving that it has extremely strong structural stability.

[0041] Particle size analysis: The particle size of nanomaterials has an impact on the body. In the range of 10-150 nm, nanomaterials can trigger oxidative stress responses in the body, causing inflammation or cell death. To avoid the aforementioned nanotoxicity problems caused by residual hemostatic materials in the body, this invention limits the particle size of the hemostatic materials to no less than 200 nm. The hemostatic materials in each embodiment are screened with a particle size of 200 nm or larger to meet the requirements.

[0042] The test results of the rat tail-cutting hemostasis experiment for each embodiment and comparative example are as follows: By comparing the weight of the sample bottle before and after bleeding, the amount of bleeding in the rat can be calculated, and the rapid hemostasis ability of the hemostatic material can be evaluated. As shown in Table 2, each embodiment achieved a superior hemostatic effect compared to the comparative example. Specifically, the hemostatic effects of Examples 1 and 4 are superior to ZIF-8 in Comparative Example 1. It should be noted that the hemostatic mechanism of ZIF-8 differs from that of the hemostatic materials disclosed in this invention. As mentioned above, ZIF-8 achieves hemostasis by adsorbing and activating thrombin activity in the blood through specific crystal facets (such as {100} and {110}). Therefore, the synthesis of ZIF-8 hemostatic material requires special modifiers or processing steps; while the hemostatic mechanism of the hemostatic materials in each embodiment of this invention is achieved by adsorbing water from the blood, concentrating the hemostatic factor, and thus accelerating hemostasis. In addition to the hemostatic specificity of ZIF-8, the imidazole ligands produced by the decomposition of ZIF-8 are biotoxic, and their safety is significantly lower than that of the hemostatic materials in each embodiment of this invention. Compared to the Mg-GA hemostatic material in Comparative Example 2, the hemostatic materials in each embodiment showed significantly superior hemostatic effects. Taking Example 1 as an example, the bleeding volume was reduced by 30% compared to that in Comparative Example 2 (Mg-GA). This is because Mg-GA has insufficient stability and is prone to decomposition during hemostasis. Structural damage leads to a significant decrease in its hemostatic ability, and this hemostatic material also has a small specific surface area (~100 m²). 2 (g), with few water adsorption sites. This material, Mg-GA, is typically used as an anti-inflammatory and antibacterial agent because of the Mg produced after its decomposition. 2+ Gallic acid has anti-inflammatory and antibacterial properties, and when used in combination with other hemostatic agents, it achieves hemostasis and antibacterial effects. However, it cannot achieve rapid hemostasis when used alone. Compared to Comparative Example 3 (zeolite material), the bleeding amount in Example 1 was reduced by 26%; compared to Comparative Example 4 (commercial Yunnan Baiyao hemostatic powder), the bleeding amount in Example 1 was reduced by 31%; and compared to Comparative Example 5 (blank group), the bleeding amount in Example 1 was reduced by 54%. Through the above comparative analysis, the hemostatic material disclosed in this invention demonstrates excellent rapid hemostatic effect.

[0043] Table 2 Results of the rat tail-cutting hemostasis experiment Group Amount of bleeding / g Example 1 1.0531 Example 2 1.1639 Example 3 1.2286 Example 4 0.9546 Comparative Example 1 1.1265 Comparative Example 2 1.5019 Comparative Example 3 1.4237 Comparative Example 4 1.5267 Comparative Example 5 2.2669 Temperature rise experiment: Sufficient amounts of the hemostatic material from Example 1 and the zeolite material from Comparative Example 3 were added to two plastic test tubes, respectively. Then, 1 mL of water was added to each. Upon absorbing water, the materials released heat, causing their temperature to rise. The temperature changes inside the test tubes were observed using an infrared thermal imager. Figure 2 , Figure 3When 1 mL of water was completely absorbed, the zeolite material released more heat, causing the highest temperature inside the test tube to reach 19°C; while the hemostatic material in Example 1, after absorbing 1 mL of water, had a test tube temperature of 17.9°C, a temperature difference of 1.1°C. Human blood volume is approximately 7-8% of body weight, and plasma accounts for about 55% of blood, with water making up 90-92% of plasma. Blood loss exceeding 30% can be life-threatening. For a body weight of 60 kg, a 30% blood loss would involve approximately 700 mL of water. Considering practical operation, the hemostatic material cannot completely absorb all the water in the lost blood; however, even absorbing only a few hundred milliliters of water can amplify the temperature difference to tens of degrees Celsius. Therefore, the hemostatic materials of the various embodiments of this invention can significantly reduce burns caused by temperature rise due to adsorption heat. To further explain this part, we consider the heat of adsorption of the two materials. The heat of adsorption of the zeolite material used is about 57.7 kJ / mol, while the heat of adsorption of the hemostatic material in Example 1 is about 40 kJ / mol, which is about 31% lower, and therefore the heat release is smaller.

[0044] Biotoxicity testing: The assay used matrix gel drug delivery at concentrations of 50 mg / mL, 100 mg / mL, 150 mg / mL, and 200 mg / mL (control group: 0 mg / mL). The cells were cultured at 37°C and 5% CO2 for 4 days, with daily medium changes. After the assay, liver organoid morphology and cell viability were analyzed. Figure 4-5 The morphology of liver organoids was recorded at 0 and 96 h after intradermal administration of the matrix gel at the indicated concentration. No obvious apoptosis of liver organoids was found within 96 h, indicating that the hemostatic material in the example has good biocompatibility. Figure 6 The results of the cell viability test of the hemostatic material in Example 1 show that the nanomaterials are non-cytotoxic within the range of 200 mg / mL.

[0045] In summary, the hemostatic material disclosed in this invention can achieve rapid hemostasis. The hemostasis process is gentle and does not release a large amount of heat, thus avoiding burns. The hemostatic material has a stable structure and will not decompose in the wound environment, thereby reducing its hemostatic effect. It also does not produce biotoxic decomposition products and has excellent biocompatibility.

Claims

1. A rapid hemostatic material, characterized by: The hemostatic material is a metal organic framework material formed by metal ions and organic ligands; the metal ions are aluminum ions.

2. The rapid hemostatic material of claim 1, wherein: The organic ligands are selected from one or more of terephthalic acid, isophthalic acid, trimesic acid, fumaric acid, 2,5-furandicarboxylic acid, 3,5-pyrazole dicarboxylic acid, amino acid, citric acid, malic acid, succinic acid, polypeptide, sugar, adipic acid, sebacic acid, and derivatives of the above substances.

3. The rapid hemostatic material of claim 2, wherein: The organic ligands are selected from one or more of terephthalic acid, isophthalic acid, trimesic acid, fumaric acid, and derivatives of the above substances.

4. A rapid hemostatic material according to any one of claims 1 to 3, characterized in that: The hemostatic material has structural stability, which means that the rapid hemostatic material does not decompose in structures in an environment with a pH of 2-11.

5. A rapid hemostatic material according to any one of claims 1-3, characterized in that: The BET specific surface area of the hemostatic material is not less than 600 m 2 / g.

6. A rapid hemostatic material according to any one of claims 1-3, characterized in that: The particle size of the hemostatic material is not less than 200 nm, and no nanotoxicity is generated.

7. Use of a rapid hemostatic material according to any one of claims 1 to 6, characterized in that: The hemostatic material is applied as a hemostatic active ingredient to various hemostatic medical products, such as hemostatic dressings, hemostatic gauze, hemostatic bandages, hemostatic sponges, hemostatic cotton balls, hemostatic gels, and hemostatic adhesive bandages.

Images